Mario Bustos Rodriguez, MD
Endocrinology, Diabetes & Metabolism · Tulsa, OKNPI 1700265584
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 664 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 16.3% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,903, 3.7 times the $1,065 reported in 2020.
Across 664 payments — averaging $28.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$3K
- Abbott$3K
- AstraZeneca$2K
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- plus $6K from 32 others
What the payments were for
- Food & beverage$18,45198%
- Education$2902%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 117 | $3,049 |
| Abbott | 77 | $2,643 |
| AstraZeneca(2 entities) | 79 | $2,304 |
| Novo Nordisk | 80 | $1,939 |
| Boehringer Ingelheim | 42 | $1,329 |
| Lilly USA, LLC | 56 | $1,160 |
| Amgen(2 entities) | 34 | $1,041 |
| Bayer | 22 | $855 |
| Insulet Corporation | 18 | $671 |
| Medtronic(2 entities) | 7 | $423 |
| Tandem Diabetes Care, Inc. | 13 | $412 |
| Xeris Pharmaceuticals, Inc. | 15 | $321 |
| Mannkind Corporation | 8 | $296 |
| Neurocrine Biosciences, Inc. | 6 | $248 |
| AbbVie | 15 | $244 |
| Ultragenyx Pharmaceutical Inc. | 9 | $197 |
| Antares Pharma, Inc. | 2 | $151 |
| Corcept Therapeutics | 6 | $148 |
| Astellas Pharma US Inc | 5 | $132 |
| Sanofi-aventis U.S. LLC | 1 | $127 |
| Esperion Therapeutics, Inc. | 6 | $119 |
| BETA Bionics, Inc. | 5 | $116 |
| Chiesi USA, Inc. | 5 | $109 |
| Amarin Pharma, Inc. | 6 | $108 |
| Ascendis Pharma Endocrinology Inc | 4 | $106 |
| Recordati_rare_diseases_inc. | 3 | $70 |
| IBSA Pharma Inc. | 3 | $63 |
| Currax Pharmaceuticals LLC | 4 | $59 |
| Amryt Pharma Holdings Ltd | 3 | $56 |
| Novartis | 2 | $38 |
| OPKO Pharmaceuticals, LLC | 2 | $36 |
| Nevro Corp. | 2 | $36 |
| Endo Pharmaceuticals Inc. | 2 | $30 |
| Madrigal Pharmaceuticals | 1 | $28 |
| Rhythm Pharmaceuticals, Inc. | 1 | $24 |
| ANI Pharmaceuticals, Inc. | 1 | $23 |
| Intra-sana Laboratories | 1 | $15 |
| GRT US Holding, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G6 TRANSMITTER$1,258
- FREESTYLE LIBRE 3$1,109
- FARXIGA$1,101
- JARDIANCE$928
- FreeStyle Libre 2$744
- Kerendia$587
- EVENITY$359
- Wegovy$236
- MINIMED 780G$228
- AFREZZA$155
- Minimed 770G System$146
- TZIELD$127
- Omnipod$127
- TLANDO$123
- XYOSTED$123
- CRENESSITY$121
- Prolia$120
- t:slim X2 Insulin Pump with Control-IQ$119
- RYBELSUS$118
- ZEPBOUND$117
How this compares
$18,742 in reported general payments places this provider in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
See all endocrinology, diabetes & metabolism providers in Oklahoma →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 530 | $622,959 |
| FarxigaDapagliflozin Propanediol | 337 | $360,831 |
| TrulicityDulaglutide | 251 | $301,232 |
| JardianceEmpagliflozin | 215 | $244,365 |
| MounjaroTirzepatide | 40 | $56,780 |
| Novolog FlexpenInsulin Aspart | 252 | $51,011 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 210 | $36,801 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 82 | $36,280 |
| Tresiba Flextouch U-100Insulin Degludec | 60 | $36,008 |
| Teriparatide | 14 | $34,397 |
| Humalog Kwikpen U-100Insulin Lispro | 89 | $29,555 |
| Tresiba Flextouch U-200Insulin Degludec | 19 | $22,844 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 17 | $14,514 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 14 | $14,400 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 55 | $7,691 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $1,939 | $625,921547 claims |
| AstraZenecaFarxiga | $2,304 | $360,831337 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $1,160 | $360,423308 claims |
| Boehringer IngelheimJardiance | $1,329 | $244,365215 claims |
| AbbVieSynthroid | $244 | $7,17668 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 61 endocrinology, diabetes & metabolism providers in Oklahoma.
Other endocrinology, diabetes & metabolism in Tulsa
- Cristin BrunsTulsa$159K
- Donald AspensonTulsa$153K
- Hanna FoggTulsa$25K
- Elie AbedTulsa$10K
- Vishnu Priya PulipatiTulsa$8K
- Maria VargasTulsa$7K
- Christian HansonTulsa$4K
- Miguel Jara PalaciosTulsa$4K
- Deepa PhilipTulsa$4K
- Alekya PolojuTulsa$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.